Discover Pharmaron's Advanced AAV Gene Therapy Platform! At Pharmaron, we have developed a robust platform process for creating AAV gene therapies, equipped with a highly adaptive toolbox to manage various AAV products and serotypes. Our innovative toolbox allows us to rapidly assess a product’s compatibility with our platform and finely tune multiple parameters for optimal results. Learn more by downloading our poster: Utilising HTPD and DoE to Optimise the Pharmaron Gene Therapy Platform: https://lnkd.in/e9w2Xj7c #GeneTherapy #AAV #Biotechnology #Pharmaron #HTPD #DoE #Innovation
Pharmaron Biologics (UK) Ltd’s Post
More Relevant Posts
-
New Regulatory Standards for Gene Therapy: The European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe has introduced a new monograph, Gene Therapy Medicinal Products for Human Use (3186), replacing the previous chapter, Gene Transfer Medicinal Products (5.14). This update sets clearer requirements for GTMPs, including genetically modified cells and viral vectors. These changes, effective April 2025, mark a significant step toward standardized control of advanced therapies. At PathoQuest, we are fully aligned with these new standards to ensure the safety and quality of gene therapy products. Learn more: 🔗 https://lnkd.in/gGKsjwRU
To view or add a comment, sign in
-
Despite some high profile stumbles, gene therapies remain projected to grow in market size significantly over the next decade. With an average CAGR of about 19%, the market should grow from $3.19 billion in 2023 to over $18 billion in 2033. There is a robust gene therapy pipeline industry wide, and many patients are counting on therapies in development as their only hope of effective treatment. With advancements in gene editing, vector development and production and delivery mechanisms, the healing potential grows every year. https://lnkd.in/gHt3mWUt
To view or add a comment, sign in
-
#Article now available! Evaluation and performance of an #AAVaffinityresin: a #CDMO case study There are now six #AAV-based #genetherapy products on the market, with many more in the R&D pipeline, which has led to an increased demand for the development of efficient and robust downstream purification processes to ensure the production of high-quality AAV vectors. This article introduces POROS™ CaptureSelect™ AAVX affinity resins for the scalable #downstreampurification of a range of #AAVserotypes for gene therapy applications. Read this article at your convenience below:
Evaluation and performance of an AAV affinity resin: a CDMO case study
insights.bio
To view or add a comment, sign in
-
#Article now available! Evaluation and performance of an #AAVaffinityresin: a #CDMO case study There are now six #AAV-based #genetherapy products on the market, with many more in the R&D pipeline, which has led to an increased demand for the development of efficient and robust downstream purification processes to ensure the production of high-quality AAV vectors. This article introduces POROS™ CaptureSelect™ AAVX affinity resins for the scalable #downstreampurification of a range of #AAVserotypes for gene therapy applications. Read this article at your convenience below: https://buff.ly/4dlDmLN
https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/3191/evaluation-and-performance-of-an-aav-affinity-resin-a-cdmo-case-study?utm_medium=social&utm_source=linkedin%20&utm_campaign=c_tfpu_305nt
insights.bio
To view or add a comment, sign in
-
Check out the latest from Circio in this interview with Drug Target Review
🔊 Latest article! 💡Enhancing gene therapy with Circio In this Q&A, Erik Digman Wiklund, CEO of Circio Holding ASA explains the key findings of their circVec circular RNA platform technology, why they chose AAV-based gene therapy for AATD as the lead programme, and their plans for the future to enhance the potency and reduce the cost of current gold-standard gene therapy. Click the link in the comments to read more! 👇 #genetherapy #RNA #AATD
To view or add a comment, sign in
-
Delighted to share the published article by Pharmaron's Spyros Gerontas, Snr. Technical Specialist and Thermo Fisher Scientific entitled '𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗼𝗳 𝗮𝗻 𝗔𝗔𝗩 𝗔𝗳𝗳𝗶𝗻𝗶𝘁𝘆 𝗥𝗲𝘀𝗶𝗻: 𝗔 𝗖𝗗𝗠𝗢 𝗖𝗮𝘀𝗲 𝗦𝘁𝘂𝗱𝘆'. The article introduces POROS™ CaptureSelect™ AAVX affinity resins for the scalable downstream purification of a range of AAV serotypes for GT applications, along with Pharmaron's case study analysing the performance of the resin. Check out the article below ⬇ on Cell & Gene Therapy Insights website. #cdmo #aav #genetherapies #AAVXaffinityresins #downstreamprocessing #pharmaron
#Article now available! Evaluation and performance of an #AAVaffinityresin: a #CDMO case study There are now six #AAV-based #genetherapy products on the market, with many more in the R&D pipeline, which has led to an increased demand for the development of efficient and robust downstream purification processes to ensure the production of high-quality AAV vectors. This article introduces POROS™ CaptureSelect™ AAVX affinity resins for the scalable #downstreampurification of a range of #AAVserotypes for gene therapy applications. Read this article at your convenience below:
Evaluation and performance of an AAV affinity resin: a CDMO case study
insights.bio
To view or add a comment, sign in
-
Providing Solutions & Technologies to Enterprises & Scientists for advancing the manufacturing of precision medicines
Embrace the future of gene therapies with ELEVECTA producer cell line. Large-scale viral vector manufacturing encounters hurdles like batch variability caused by transient transfection. ELEVECTA producer cell line provides the remedy by having all components stably integrated. Production starts simply by adding an induction reagent. This one-step process ensures robustness and scalability for your gene therapy endeavors. Learn more: https://lnkd.in/g6yHrnsg #ELEVECTAproducercellline #celllinedevelopment
To view or add a comment, sign in
-
Embrace the future of gene therapies with ELEVECTA producer cell line. Large-scale viral vector manufacturing encounters hurdles like batch variability caused by transient transfection. ELEVECTA producer cell line provides the remedy by having all components stably integrated. Production starts simply by adding an induction reagent. This one-step process ensures robustness and scalability for your gene therapy endeavors. Learn more: https://lnkd.in/gBNsq_kF #ELEVECTAproducercellline #celllinedevelopment
To view or add a comment, sign in
-
🔊 Latest article! 💡Enhancing gene therapy with Circio In this Q&A, Erik Digman Wiklund, CEO of Circio Holding ASA explains the key findings of their circVec circular RNA platform technology, why they chose AAV-based gene therapy for AATD as the lead programme, and their plans for the future to enhance the potency and reduce the cost of current gold-standard gene therapy. Click the link in the comments to read more! 👇 #genetherapy #RNA #AATD
To view or add a comment, sign in
-
Embrace the future of gene therapies with ELEVECTA producer cell line. Large-scale viral vector manufacturing encounters hurdles like batch variability caused by transient transfection. ELEVECTA producer cell line provides the remedy by having all components stably integrated. Production starts simply by adding an induction reagent. This one-step process ensures robustness and scalability for your gene therapy endeavors. Learn more: https://lnkd.in/g6nARmj6 #ELEVECTAproducercellline #celllinedevelopment
To view or add a comment, sign in
10,773 followers
Specialist in LinkedIn Media Management, Archivist/ Project Consultant for the Ministry of Planning and Budget
2moQue legal 😃